Have we reached the limits for the treatment of diabetic nephropathy? Review uri icon

Overview

MeSH Major

  • Diabetic Nephropathies

abstract

  • Although issues around validity of surrogate markers and clinical end points have complicated trial data in the field, currently available evidence is not persuasive as regards the clinical application of these agents. There remains a clear and growing need for emerging therapeutics to be used in combination with RAAS blocking agents.

publication date

  • January 2014

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1517/13543784.2014.892580

PubMed ID

  • 24555907

Additional Document Info

start page

  • 511

end page

  • 22

volume

  • 23

number

  • 4